The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

Hims & Hers Health (HIMS) is trying its best to stay relevant in the multi-billion dollar obesity treatment market. Despite a ...

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a ...

The FDA's new rule restricting the sale of compounded semaglutide could make it more difficult for some people to obtain ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Hims & Hers Health said it is expanding its weight-loss offerings with the addition of Eli Lilly & Co. Zepbound and generic ...

Joelle Pineau said she would step down effective May 30, creating an executive vacancy as the company aggressively invests and competes in the booming sector. Visa, Amex and Mastercard are all ...